T cell response to tumor antigens and its therapeutic use in cancer patients

  • Giorgio Parmiani
  • Chiara Castelli
  • Piero Dalerba
  • Licia Rivoltini
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 495)


The molecular characterization of human tumor antigens has allowed a rapid translation of information gained in basic research into clinical protocols. Melanoma is the tumor that was more frequently studied thanks to several clinical reports suggesting its antigenicity and to the availability of tumor cell lines and autologous T lymphocyte lines or clones that can be obtained from the majority of patients and used forin vitrostudies’. However, several other tumor histotypes have been also analyzed though with less clear-cut results.


Tumor Antigen Melanoma Patient Metastatic Melanoma Patient Unique Antigen Tumor Histotypes 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Parmiani, G., Anichini, A., and Fossati, G., 1990, Cellular immune response against autologous human malignant melanoma: are in vitro studies providing a framework for a more effective immunotherapy? J. Natl. Cancer Inst. USA 82: 361–370.CrossRefGoogle Scholar
  2. 2.
    Van der Bruggen, P., Traversari, C., Chomez, P., Lurquin, C., De Plaen, E., Van den Eynde, B., Knuth, A., and Boon, T., 1991, A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254: 1643–1647.PubMedCrossRefGoogle Scholar
  3. 3.
    Cox, A.L., Skipper, J., Chen, Y., Henderson, R.A., Darrow, T.L., Shabanowitz, J., Engelhard, V.H., Hunt, D.F., and Slingluff, C.L. Jr., 1994, Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science 264: 716–719.PubMedCrossRefGoogle Scholar
  4. 4.
    Renkvist, N., Castelli, C. Robbins, P., and Parmiani, G., 2001, A listing of tumor antigens recognized by T cells. Cancer Immunol. Immunother., in press.Google Scholar
  5. 5.
    Chen, Y.T., Scanlan, M.J., Sahin, U., Tureci, O., Gure, A.O., Tsang, S., Williamson, B., Stockert, E., Pfreundschuh, M., and Old, L.J., 1997, A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc. Natl. Acad. Sci. USA 94: 1914–1918.PubMedCrossRefGoogle Scholar
  6. 6.
    Schuler-Thurner, B., Dieckmann, D., Keikavoussi, P., Bender, A., Maczek, C., Jonuleit, H., Roder, C., Haendle, I., Leisgang, W., Dunbar, R., Cerundolo, V., von den Driesch, P., Knop, J., Brocker, E.B., Enk, A., Kampgen, E., and Schuler, G., 2000, Mage-3 and influenza-matrix peptide-specific cytotoxic T cells are inducible in terminal stage HLAA2.1+ melanoma patients by mature monocyte-derived dendritic cells. J. Immunol. 165: 3492–3496.PubMedGoogle Scholar
  7. 7.
    Anichini, A., Maccalli, C., Mortarini, R., Salvi, S., Mazzocchi, A., Squarcina, P., Herlyn, M., and Parmiani, G., 1993, Melanoma cells and normal melanocytes shared antigens recognized by HLA-A2 restricted cytotoxic T cell clones from melanoma patients. J. Exp. Med. 177: 989–998.PubMedCrossRefGoogle Scholar
  8. 8.
    Rivoltini, L., Kawakami, Y., Sakaguchi, K., Southwood, S., Sette, A., Robbins, P.F., Marincola, F., Salgaller, M., Yannelli, J.R., Appella, E., and Rosenberg, S.A., 1995, Induction of tumor-reactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1. J. Immunol. 154: 2257–2265.PubMedGoogle Scholar
  9. 9.
    Guilloux, Y., Lucas, S., Brichard, V.G., Van Pel, A., Viret, C., De Plaen, E., Brasseur, F., Lethé, B., Jotereau, F., and Boon, T., 1996, A peptide recognized by human cytolytic T lymphocytes on HLA-A2 melanomas is encoded by an intron sequence of the Nacetylglucosaminyltransferase V gene. J. Exp. Med. 183: 1173–1183.PubMedCrossRefGoogle Scholar
  10. 10.
    Lupetti, R., Pisarra, P., Verrecchia, A., Farina, C., Nicolini, C., Anichini, A., Bordignon, C., Sensi, M., Parmiani, G., and Traversari, C., 1998, Translation of a retained intron in tyrosinase-related protein (TRP) 2 mRNA generates a new cytotoxic T lymphocyte (CTL)defined and shared human melanoma antigen not expressed in normal cells of the melanocytic lineage. J. Exp. Med. 188: 1005–1016.PubMedCrossRefGoogle Scholar
  11. 11.
    Topalian, S.L., Rivoltini, L., Mancini, M., Markus, N.R., Robbins, P.F., Kawakami, Y., and Rosenberg, S.A., 1994, Human CD4+ T cells specifically recbgnize a shared melanoma-associated antigen encoded by the tyrosinase gene. Proc. Natl. Acad. Sci. USA 91: 9461–9465.PubMedCrossRefGoogle Scholar
  12. 12.
    Zeng, G., Touloukian, C.E., Wang, X., Restifo, N.P., Rosenberg, S.A., and Wang, R-F-, 2000, Identification of CD4+ T cell epitopes from NY-ESO-1 presented by HLA-DR molecules. J. Immunol. 165: 1153–1159.PubMedGoogle Scholar
  13. 13.
    Srivastava, P.K., Menoret, A., Basu, S., Binder, R.J., and McQuade, K.L., 1998, Heat shock proteins come of age: Primitive functions acquire new roles in an adaptive world. Immunity 8: 657–665.PubMedCrossRefGoogle Scholar
  14. 14.
    Castelli, C., Ciupitu, A.-M.T., Rini, F., Rivoltini, L., Mazzocchi, A., Kiessling, R, and Parmiani, G., 2001, Human HSP70-peptide complexes specifically activate anti-melanoma T-cells. Cancer Res. in press.Google Scholar
  15. 15.
    Anichini, A., Molla, A., Mortarini, R., Tragni, G., Bersani, I., Di Nicola, M., Gianni, A.M., Pilotti, S., Dunbar, R., Cerundolo, V., and Parmiani, G., 1999, An expanded peripheral T cell population to a cytotoxic T lymphocyte (CTL)-defined melanocytespecific antigen in metastatic melanoma patients impacts on generation of peptide-specific CTLs but does not overcome tumor escape from immune surveillance in metastatic lesions. J. Exp. Med. 190: 651–667.PubMedCrossRefGoogle Scholar
  16. 16.
    Di Nicola, M., Anichini, A., Mortarini, R., Bregni, M., Parmiani, G., and Gianni, M., 1998, Human dendritic cells: natural adjuvants in antitumor immunotherapy. Cytok. Cell. Mol. Ther. 4: 265–273.Google Scholar
  17. 17.
    Thurner, B., Haendle, I., Roder, C., Dieckman, D., Keikavoussi, P., Jonuleit, H., Bender, A., Maczek, C., Schreiner, D., von den Driesch, P., Brocker, E.B., Steinman, R.M., Enk, A., Kampgen, E., and Schuler, G., 1999, Vaccination with Mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J. Exp. Med. 190: 1669-1678.PubMedCrossRefGoogle Scholar
  18. 18.
    Marchand, M., van Baren, N., Weynants, P., Brichard, V., Dréno, B., Tessier, M.H., Rankin, E., Parmiani, G., Arienti, F., Humbler, Y., Bourlond, A., Vanwijck, R., Liénard, D., Beauduin, M., Dietrich, P.Y., Russo, V., Kerger, J., Masucci, G., Jager, E., De Greve, J., Atzpodien, J., Brasseur, F., Coulie, P.G., van der Bruggen, P., and Boon, T., 1999, Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int. J.Cancer 32: 717–721.Google Scholar
  19. 19.
    Rosenberg, S.A., Yang, J.C., Schwartzentruber, D.J., Hwu, P., Marincola, F.M., Topalian, S.L., Restifo, N.P., Dudley, M.E., Schwarz, S.L., Spiess, P.J., Wunderlich, J.R., Parkhurst, M.R., Kawakami, Y., Seipp, C.A., Einhor, J.H., and White, D.E., 1998, Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nature Med. 4: 321–327.PubMedCrossRefGoogle Scholar
  20. 20.
    Janetzki, S., Palla, D., Rosenhauer, V., Lochs, H., Lewis, J.J., and Srivastava, P.K., 2000, Immunization of cancer patients with autologous cancer-derived heat shock protein gp96 preparations: a pilot study. Int. J. Cancer 88: 232–238.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2001

Authors and Affiliations

  • Giorgio Parmiani
    • 1
  • Chiara Castelli
    • 1
  • Piero Dalerba
    • 1
  • Licia Rivoltini
    • 1
  1. 1.Unit of Immunotherapy of Human CancerIstituto Nazionale TumoriMilanoItaly

Personalised recommendations